強化劑量阿托伐他汀對不穩(wěn)定型心絞痛患者PCI圍手術(shù)期B7-H3及B7-H4的影響
發(fā)布時間：2019-02-11 21:09
【摘要】：研究背景不穩(wěn)定型心絞痛(Unstable angina,UA)的發(fā)病的機制是在動脈粥樣硬化的基礎(chǔ)上冠脈內(nèi)不穩(wěn)定的粥樣斑塊繼發(fā)病理改變,使局部心肌血流量明顯下降,如斑塊內(nèi)出血、斑塊纖維帽出血裂隙、表面上有血小板聚集及(或)刺激冠狀動脈痙攣,導(dǎo)致缺血加重。不穩(wěn)定型心絞痛是冠心病的常見類型之一,既往大量研究表明慢性免疫炎癥反應(yīng)貫穿于在動脈粥樣硬化的過程,炎癥遞質(zhì)激活效應(yīng)細胞產(chǎn)生炎性因子,進而可影響斑塊纖維帽的穩(wěn)定性促使動脈粥樣硬化斑塊內(nèi)出現(xiàn)破裂、出血,最后導(dǎo)致不穩(wěn)定斑塊的形成。B7-H3和B7-H4是近些年來研究較熱的B7共刺激分子家族新成員。最新研究證實人和鼠的B7-H3、B7-H4都能有效抑制CD4+T淋巴細胞激活和炎性因子如干擾素-γ(Interferon-γ,IFN-γ)、白細胞介素-4(Interleukin-4,IL-4)的產(chǎn)生的作用,并可負性調(diào)節(jié)T淋巴細胞活化。張小民團隊等人關(guān)于B7-H3的探索發(fā)現(xiàn)頸動脈硬化患者血清可溶性B7-H3(s B7-H3)分泌水平較健康對照組明顯升高。既往對這兩個指標的研究主要局限于腫瘤性疾病,關(guān)于B7-H3、B7-H4與動脈粥樣硬化(atherosclerosis,AS)之間的關(guān)系的研究罕見報道。目的探討強化劑量阿托伐他汀對不穩(wěn)定型心絞痛患者經(jīng)皮冠狀動脈介入術(shù)(Percutaneous coronary intervention,PCI)圍手術(shù)期B7-H3及B7-H4的表達的影響。方法將80例不穩(wěn)定型心絞痛患者按隨機數(shù)字表法分為強化劑量阿托伐他汀組(n=40)和常規(guī)劑量阿托伐他汀組(n=40),強化劑量組于PCI術(shù)前48h口服阿托伐他汀80mg/d治療,術(shù)后給阿托伐他汀40 mg/d;常規(guī)劑量組于PCI術(shù)前48h、術(shù)后口服阿托伐他汀20mg/d治療。分別于PCI術(shù)前、術(shù)后18-24h收集患者外周靜脈血,酶聯(lián)免疫吸附試驗(Enzyme-linked immuno sorbent assay,ELISA)檢測血清IL-4、IL-10、IFN-γ、s B7-H3、s B7-H4濃度水平,用實時熒光定量PCR反應(yīng)(Realtime fluorescent quantitative Reverse transcription-polymerase chain reaction,q RT-PCR)檢測外周血單核細胞(Peripheral blood mononuclear cell,PBMC)B7-H3m RNA和B7-H4m RNA相對表達量。結(jié)果(1)PCI術(shù)前,兩組患者血清IL-4、IL-10、IFN-γ濃度水平無統(tǒng)計學(xué)差異(P0.05);PCI術(shù)后,常規(guī)劑量組和強化劑量組患者血清IL-4、IFN-γ濃度水平較術(shù)前降低,其中強化劑量組下降更明顯,差異有統(tǒng)計學(xué)差異(P0.05);相反,血清IL-10濃度水平較術(shù)前上升,而且強化劑量組血清IL-10水平升高更顯著,差異有統(tǒng)計學(xué)差異(P0.05);(2)PCI術(shù)前,兩組患者s B7-H3、s B7-H4濃度水平無明顯差異(P0.05);PCI術(shù)后,兩組患者s B7-H3、s B7-H4濃度水平均上升,其中強化劑量組s B7-H3、s B7-H4水平升高更顯著,差異有統(tǒng)計學(xué)意義(P0.05);(3)PCI術(shù)前,兩組患者B7-H3m RNA、B7-H4m RNA表達水平無顯著差異(P0.05);PCI術(shù)后,常規(guī)劑量組PCI術(shù)后B7-H3、B7-H4m RNA表達水平較術(shù)前無明顯變化,差異無統(tǒng)計學(xué)意義(P0.05);強化劑量組B7-H3、B7-H4m RNA表達較術(shù)前明顯升高,差異有統(tǒng)計學(xué)意義(P0.05);(4)線性相關(guān)分析顯示:B7-H3 m RNA與IL-10呈正性相關(guān),相關(guān)系數(shù)r=0.629,(P0.05),與IL-4、IFN-γ水平分別呈負性相關(guān)(r=-0.342,r=-0.417,均P0.05);B7-H4m RNA與IL-10呈正性相關(guān)(r=0.599,P0.05),與IL-4、IFN-γ分別呈負性相關(guān)(r=-0.391,r=-0.458,均P0.05)。結(jié)論強化劑量阿托伐他汀可能通過促進B7-H3、B7-H4表達,從而降低不穩(wěn)定型心絞痛患者PCI圍手術(shù)期免疫炎癥反應(yīng)。
[Abstract]:The mechanism of the study on the pathogenesis of unstable angina (UA) is the secondary pathological change of the unstable atherosclerotic plaque on the basis of the atherosclerosis, so that the local myocardial blood flow is obviously reduced, such as the plaque hemorrhage, the plaque fiber cap hemorrhage fracture, Platelet aggregation and/ or stimulation of coronary artery spasm on the surface leads to an increase in ischemia. unstable angina is one of the most common types of coronary heart disease, and a large number of previous studies have shown that the chronic immune inflammatory response runs through the process of atherosclerosis, the inflammatory and active effect cells producing an inflammatory factor, further, the stability of the plaque fiber cap can be affected to cause a rupture and a hemorrhage in the atherosclerotic plaque, and finally, the formation of the unstable plaque can be caused. B7-H3 and B7-H4 are new members of the B7 costimulatory molecule family that have been studied in recent years. The most recent studies confirm that both B7-H3 and B7-H4 of human and mouse can effectively inhibit the activation of CD4 + T lymphocytes and the effect of inflammatory factors such as Interferon-1 (IFN-1), interleukin-4 (Interleukin-4, IL-4), and can negatively regulate the activation of T-lymphocytes. The results showed that the level of serum soluble B7-H3 (s 7-H3) in the patients with carotid arteriosclerosis was significantly higher than that in the healthy control group. Previous studies of these two indicators are mainly limited to the neoplastic disease, and the study of the relationship between B7-H3, B7-H4 and atherosclerosis (AS) is rare. Objective To investigate the effect of intensive dose of atorvastatin on the expression of B7-H3 and B7-H4 in patients with unstable angina undergoing percutaneous coronary intervention (PCI). Methods 80 patients with unstable angina were divided into intensive dose of atorvastatin (n = 40) and conventional dose of atorvastatin (n = 40). The conventional dose group was treated with atorvastatin 20mg/ d before and after PCI. Serum IL-4, IL-10, IFN-1, s B7-H3, s B7-H4 concentration levels were detected by enzyme-linked immunosorbent assay (ELISA) before and after PCI, and the real-time fluorescence quantitative PCR reaction was used. The relative expression of B7-H3m and B7-H4m in peripheral blood mononuclear cells (PBMC) was detected by q-RT-PCR. Results (1) Before PCI, the levels of IL-4, IL-10 and IFN-2 in serum of the two groups were not significantly different (P0.05). The levels of IL-4 and IFN-1 in the patients with conventional and intensive dose groups were lower than that before PCI. There was a significant difference in serum IL-10 concentration in the two groups (P0.05). In contrast, the level of serum IL-10 increased significantly, and the level of serum IL-10 in the intensive dose group was higher and the difference was statistically different (P0.05); (2) Before PCI, there was no significant difference between the two groups of patients's B7-H3, s B7-H4 (P0.05); after PCI, The levels of sB7-H3 and sB7-H4 in the two groups increased, and the level of B7-H3, s B7-H4 was higher in the two groups, and the difference was significant (P0.05). (3) The expression of B7-H3m RNA and B7-H4m in the two groups was not significantly different (P0.05). There was no significant difference in the expression of B7-H4m (P0.05). The expression of B7-H3 and B7-H4m in the intensive dose group was significantly higher than that before operation (P0.05). (4) The linear correlation analysis showed that the B7-H3 mRNA was positively related to IL-10, and the correlation coefficient was r = 0.629. (P <0.05), and negative correlation with IL-4 and IFN-1 levels (r =-0.342, r =-0.417, all P0.05); the positive correlation between B7-H4m and IL-10 (r =-0.599, P0.05), and negative correlation with IL-4 and IFN-2 (r =-0.391, r =-0.458, all P0.05). Conclusion The enhanced dose of atorvastatin may be expressed by promoting the expression of B7-H3, B7-H4, thereby reducing the immune inflammatory response of PCI in patients with unstable angina.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R541.4
本文編號：2420108
[Abstract]:The mechanism of the study on the pathogenesis of unstable angina (UA) is the secondary pathological change of the unstable atherosclerotic plaque on the basis of the atherosclerosis, so that the local myocardial blood flow is obviously reduced, such as the plaque hemorrhage, the plaque fiber cap hemorrhage fracture, Platelet aggregation and/ or stimulation of coronary artery spasm on the surface leads to an increase in ischemia. unstable angina is one of the most common types of coronary heart disease, and a large number of previous studies have shown that the chronic immune inflammatory response runs through the process of atherosclerosis, the inflammatory and active effect cells producing an inflammatory factor, further, the stability of the plaque fiber cap can be affected to cause a rupture and a hemorrhage in the atherosclerotic plaque, and finally, the formation of the unstable plaque can be caused. B7-H3 and B7-H4 are new members of the B7 costimulatory molecule family that have been studied in recent years. The most recent studies confirm that both B7-H3 and B7-H4 of human and mouse can effectively inhibit the activation of CD4 + T lymphocytes and the effect of inflammatory factors such as Interferon-1 (IFN-1), interleukin-4 (Interleukin-4, IL-4), and can negatively regulate the activation of T-lymphocytes. The results showed that the level of serum soluble B7-H3 (s 7-H3) in the patients with carotid arteriosclerosis was significantly higher than that in the healthy control group. Previous studies of these two indicators are mainly limited to the neoplastic disease, and the study of the relationship between B7-H3, B7-H4 and atherosclerosis (AS) is rare. Objective To investigate the effect of intensive dose of atorvastatin on the expression of B7-H3 and B7-H4 in patients with unstable angina undergoing percutaneous coronary intervention (PCI). Methods 80 patients with unstable angina were divided into intensive dose of atorvastatin (n = 40) and conventional dose of atorvastatin (n = 40). The conventional dose group was treated with atorvastatin 20mg/ d before and after PCI. Serum IL-4, IL-10, IFN-1, s B7-H3, s B7-H4 concentration levels were detected by enzyme-linked immunosorbent assay (ELISA) before and after PCI, and the real-time fluorescence quantitative PCR reaction was used. The relative expression of B7-H3m and B7-H4m in peripheral blood mononuclear cells (PBMC) was detected by q-RT-PCR. Results (1) Before PCI, the levels of IL-4, IL-10 and IFN-2 in serum of the two groups were not significantly different (P0.05). The levels of IL-4 and IFN-1 in the patients with conventional and intensive dose groups were lower than that before PCI. There was a significant difference in serum IL-10 concentration in the two groups (P0.05). In contrast, the level of serum IL-10 increased significantly, and the level of serum IL-10 in the intensive dose group was higher and the difference was statistically different (P0.05); (2) Before PCI, there was no significant difference between the two groups of patients's B7-H3, s B7-H4 (P0.05); after PCI, The levels of sB7-H3 and sB7-H4 in the two groups increased, and the level of B7-H3, s B7-H4 was higher in the two groups, and the difference was significant (P0.05). (3) The expression of B7-H3m RNA and B7-H4m in the two groups was not significantly different (P0.05). There was no significant difference in the expression of B7-H4m (P0.05). The expression of B7-H3 and B7-H4m in the intensive dose group was significantly higher than that before operation (P0.05). (4) The linear correlation analysis showed that the B7-H3 mRNA was positively related to IL-10, and the correlation coefficient was r = 0.629. (P <0.05), and negative correlation with IL-4 and IFN-1 levels (r =-0.342, r =-0.417, all P0.05); the positive correlation between B7-H4m and IL-10 (r =-0.599, P0.05), and negative correlation with IL-4 and IFN-2 (r =-0.391, r =-0.458, all P0.05). Conclusion The enhanced dose of atorvastatin may be expressed by promoting the expression of B7-H3, B7-H4, thereby reducing the immune inflammatory response of PCI in patients with unstable angina.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R541.4
【參考文獻】
相關(guān)期刊論文 前10條
1 Bo Hong;Yun Qian;Hong Zhang;Yi-wen Sang;Lin-fang Cheng;Qi wang;Song Gao;Min Zheng;Hang-ping Yao;;Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma[J];World Journal of Gastroenterology;2016年18期
2 Joe WE Moss;Dipak P Ramji;;Interferon-γ: Promising therapeutic target in atherosclerosis[J];World Journal of Experimental Medicine;2015年03期
3 蔡明淵;蔣敬庭;;協(xié)同刺激分子B7-H4的生物學(xué)功能及臨床研究進展[J];臨床檢驗雜志;2015年04期
4 陳偉偉;高潤霖;劉力生;朱曼璐;王文;王擁軍;吳兆蘇;胡盛壽;;中國心血管病報告2013概要[J];中國循環(huán)雜志;2014年07期
5 華建江;陳望;姜健;楊慶偉;徐志康;梁巧玲;;可溶性B7-H4在早期胃癌中的診斷價值探討[J];中國免疫學(xué)雜志;2012年08期
6 陳俊俊;蔣敬庭;吳昌平;;PD-L1信號在免疫應(yīng)答中的作用及對T細胞的調(diào)控機制[J];臨床檢驗雜志;2012年06期
7 李星陽;饒紹來;;急性冠脈綜合征研究的新進展[J];中國臨床新醫(yī)學(xué);2010年07期
8 蔣敬庭;吳昌平;沈月平;鄭璐;吳駿;季枚;徐斌;陳陸俊;吳雨崗;鄭曉;朱一蓓;張學(xué)光;;共刺激分子B7-H4表達對細胞因子誘導(dǎo)的殺傷細胞治療胃癌患者預(yù)后的影響[J];中華胃腸外科雜志;2010年05期
9 張小民;趙楚敏;宋月霞;劉春榮;張光波;;新型共信號分子B7-H3表達水平與急性心肌梗死預(yù)后的關(guān)系[J];心臟雜志;2010年01期
10 廖林虹;于曉紅;;B7-H3的免疫調(diào)控及最新研究進展[J];細胞與分子免疫學(xué)雜志;2009年11期
，本文編號：2420108
本文鏈接：http://www.sikaile.net/yixuelunwen/xxg/2420108.html
最近更新
教材專著
